Approved indications: Erlotinib is FDA-approved for adults with metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 (L858R) mutations, used as first-line therapy, maintenance after chemotherapy, or after progression on at least one prior regimen, and it is also approved with gemcitabine as first-line treatment for locally advanced, unresectable or metastatic pancreatic cancer.

Off-label uses: Clinicians may use erlotinib off label for certain uncommon tumors such as papillary renal cell carcinoma or other EGFR-expressing cancers, generally when standard options are limited; evidence for these uses typically comes from small studies or early-phase trials, so benefits are less certain than for approved indications.

Efficacy expectations in EGFR-mutated NSCLC: In appropriately selected patients with EGFR-mutated metastatic NSCLC, many experience tumor shrinkage or disease control within the first 1–2 months, with disease often kept in check for many months, although most cancers eventually develop resistance and progress.

Efficacy expectations in pancreatic cancer: When added to gemcitabine for advanced pancreatic cancer, erlotinib provides a modest improvement in average survival and delay in progression compared with gemcitabine alone, so it is considered one of several options rather than a dramatically more effective therapy.

Comparison to similar drugs: Erlotinib is an older first-generation EGFR inhibitor; newer agents such as osimertinib often provide longer disease control and better brain penetration in EGFR-mutated NSCLC and are preferred first line in many guidelines, with erlotinib more commonly used when newer drugs are not available, not tolerated, or as part of specific combination regimens (for example with ramucirumab).

Typical adult dosing: For metastatic EGFR-mutated NSCLC, the usual dose is 150 mg by mouth once daily; for locally advanced, unresectable or metastatic pancreatic cancer, the usual dose is 100 mg by mouth once daily in combination with gemcitabine. Treatment generally continues as long as it is working and side effects remain acceptable, with dose reductions or temporary interruptions if significant toxicity occurs.

How to take it: Swallow the tablet whole once a day on an empty stomach, at least 1 hour before or 2 hours after food, with a glass of water, and try to take it at the same time each day. Avoid grapefruit products, and avoid breaking or crushing tablets unless your oncology team gives specific instructions.

Special dosing considerations: Cigarette smoking and certain enzyme-inducing medicines can lower erlotinib levels, so prescribers may adjust the dose upward in current smokers (and decrease it again if they stop smoking) or avoid strong CYP3A4 inducers when possible. The dose may also need to be reduced or temporarily held in people who develop significant liver or kidney test abnormalities, severe rash, or persistent diarrhea despite supportive care.

Missed dose guidance: If you miss a dose, take it as soon as you remember on an empty stomach unless it is almost time for your next scheduled dose; if it is close to the next dose, skip the missed dose and resume your regular schedule without taking two doses at once.

Overdose: Taking more than prescribed can cause severe diarrhea, skin reactions, and other serious problems; if an overdose is suspected, stop the medication and seek emergency medical attention or contact a poison control center right away.

Common side effects: The most frequent problems are acne-like rash and dry or itchy skin, diarrhea, loss of appetite, fatigue, nausea, and cough or shortness of breath. Rash and diarrhea often begin in the first few weeks of treatment, are usually mild to moderate, and can often be managed with skin care, sun protection, antidiarrheal medicines, and dose adjustments if needed.

Serious or rare adverse effects needing urgent attention: Seek immediate medical care for new or worsening breathing problems, cough, or fever (possible interstitial lung disease); severe abdominal pain or tenderness (possible gastrointestinal perforation); signs of liver injury such as yellowing of skin or eyes, dark urine, or right-sided abdominal pain; greatly decreased urination, swelling, or sudden weight gain (possible kidney injury); severe blistering or peeling skin, painful rash, or mouth sores; eye pain, redness, or vision changes (possible corneal ulcer or perforation); or chest pain, sudden weakness, confusion, or trouble speaking (possible heart attack or stroke), especially when used with gemcitabine.

Warnings and precautions: Erlotinib can harm an unborn baby, so effective contraception is recommended during treatment and for at least 1 month after the last dose, and it should generally be avoided in pregnancy unless potential benefit clearly outweighs risk. Breastfeeding is not recommended during treatment and for 2 weeks after the final dose. Safety and effectiveness in pediatric patients have not been established. People with pre-existing lung disease, liver disease, kidney problems, a history of peptic ulcer or diverticular disease, or those taking blood thinners, corticosteroids, NSAIDs, or anti-angiogenic drugs need especially careful monitoring because of higher risks of lung, liver, kidney, bleeding, or gastrointestinal complications.

Safety compared with other treatments: Compared with traditional chemotherapy, erlotinib tends to cause less bone marrow suppression (such as low blood counts) but more skin and gastrointestinal side effects; compared with some newer EGFR inhibitors, erlotinib often has higher rates of bothersome rash and diarrhea, which can limit dosing in some patients.

Monitoring and reporting: Regular blood tests are usually done to monitor liver and kidney function and electrolytes, and patients on warfarin or other coumarin anticoagulants need closer INR monitoring. Side effects should be reported promptly to the treating team, and serious adverse events can also be reported to the FDA MedWatch program by phone or online for ongoing safety surveillance.

Prescription and OTC drug interactions: Strong CYP3A4 inhibitors (such as certain azole antifungals, macrolide antibiotics, and HIV protease inhibitors) and combined CYP3A4/CYP1A2 inhibitors can raise erlotinib levels and increase toxicity, while strong CYP3A4 inducers (such as rifampin, carbamazepine, phenytoin, and St. John’s wort) and cigarette smoking can lower levels and reduce effectiveness. Drugs that reduce stomach acid, especially proton pump inhibitors, can decrease absorption; H2 blockers and antacids should be separated in time from erlotinib if they must be used. Warfarin and other coumarin anticoagulants may have an increased effect, so INR should be monitored more frequently.

Food, alcohol, and supplements: Erlotinib should be taken on an empty stomach because food, especially high-fat meals, can markedly increase drug exposure and side effects. Grapefruit and grapefruit juice can inhibit CYP3A4 and should be avoided. Alcohol has no well-defined direct interaction but can worsen liver problems, so use with caution, particularly if liver function is impaired. Herbal products such as St. John’s wort and other supplements that affect liver enzymes or stomach acid should be avoided or reviewed carefully with the oncology team.

Disease-related precautions: People with underlying lung disease, significant liver or kidney impairment, or a history of peptic ulcer disease or diverticular disease have higher risks of interstitial lung disease, hepatotoxicity, renal failure, or gastrointestinal perforation and require close monitoring and individualized risk–benefit assessment. Concomitant use of corticosteroids, NSAIDs, anti-angiogenic agents, or certain chemotherapies can further increase gastrointestinal or bleeding risks.

Monitoring needs: Routine monitoring usually includes periodic liver function tests, kidney function and electrolyte panels, and assessment for skin, eye, and lung symptoms. Patients taking warfarin require more frequent INR checks, and those on combination regimens (such as with gemcitabine or ramucirumab) may need additional cardiac or vascular monitoring based on their overall risk profile.

Q: How long will I need to take erlotinib?
A: Most people continue erlotinib as long as scans show the cancer is controlled and side effects are manageable, and it is stopped if the cancer clearly progresses or toxicity becomes unacceptable.

Q: How quickly does erlotinib start working?
A: The medicine begins acting soon after you start taking it, but doctors usually assess response with imaging after several weeks to a few months to see whether the tumors have shrunk or stabilized.

Q: Do I have to avoid the sun while on erlotinib?
A: Erlotinib commonly causes a sun-sensitive rash, so you should minimize sun exposure, wear protective clothing, and use broad-spectrum sunscreen to reduce irritation and burning.

Q: Can I take erlotinib with my other medications and supplements?
A: Many drugs and supplements, including stomach-acid reducers, certain antibiotics and antifungals, seizure medicines, warfarin, and St. John’s wort, can affect erlotinib levels or safety, so always have your full medication and supplement list reviewed before and during treatment.

Q: What should I do if I get bad diarrhea or skin rash?
A: Contact your care team promptly, because early treatment with antidiarrheal medicines and skin care, along with possible dose adjustments or brief treatment breaks, can ease symptoms and reduce the risk of serious complications.

Q: Is erlotinib safer or easier to tolerate than chemotherapy?
A: Many people find erlotinib causes fewer problems with nausea, hair loss, and low blood counts than traditional chemotherapy, but it often causes bothersome rash and diarrhea, so the side-effect pattern is different rather than universally milder.

Storage: Keep erlotinib tablets in their original container at room temperature (around 68–77°F / 20–25°C), tightly closed, away from moisture, heat, and direct light, and do not store them in the bathroom; keep out of reach of children and pets.

Handling: Swallow tablets whole and avoid crushing or breaking them unless specifically instructed; caregivers should wash hands after handling the tablets.

Disposal: When the medication is expired or no longer needed, use a community drug take-back program if available, or follow pharmacist or local waste guidance; do not flush tablets down the toilet or pour them into drains unless you are specifically told to do so.